Micrometastatic bone marrow involvement: detection and prognostic significance

Area of Science:

• Oncology
• Immunology
• Diagnostic Pathology

Background:

• Bone marrow is a common site for cancer metastasis.
• Detecting micrometastatic tumor cells is crucial for prognosis and treatment.
• Current detection methods show significant variability.

Purpose of the Study:

• To review diagnostic approaches for identifying individual cancer cells in bone marrow.
• To highlight the clinical significance of new diagnostic methods.
• To discuss the role of anti-cytokeratin antibodies in cancer detection.

Main Methods:

• Review of existing studies on bone marrow micrometastasis detection.
• Focus on immunoassays using monoclonal antibodies, specifically anti-cytokeratin antibodies (e.g., A45-B/B3).
• Analysis of prospective clinical studies correlating detection with patient prognosis.

Main Results:

• Anti-cytokeratin antibodies offer reliable detection of micrometastatic cells in bone marrow.
• Immunoassays identify patient subgroups with poor prognosis across various epithelial cancers.
• Detected disseminated cells are often dormant (Ki-67 negative), suggesting resistance to chemotherapy.

Conclusions:

• Anti-cytokeratin antibody-based immunoassays can improve tumor staging and identify high-risk patients.
• Findings support the potential of antibody-based immunotherapy as a complement to chemotherapy.
• These methods may enable monitoring of micrometastatic cell response to adjuvant therapies and guide secondary prevention strategies.